 |
 Video: What is a Stock Split?
|
|
|
| Nuvation Bio is a clinical-stage biopharmaceutical company developing therapeutic candidates focused on treating patients with cancers. Co. is developing six wholly owned compounds that have resulted from its drug discovery and development programs, which include: NUV-422, a selective small molecule inhibitor of cyclin-dependent kinase; NUV-868, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor; NUV-569, an oral small molecule selective inhibitor of Wee1 kinase, a regulator of DNA damage repair; and a drug-drug conjugate platform, which is a therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates. According to our Nuvation Bio stock split history records, Nuvation Bio has had 0 splits. | |
|
Nuvation Bio (NUVB) has 0 splits in our Nuvation Bio stock split history database.
Looking at the Nuvation Bio stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Nuvation Bio shares, starting with a $10,000 purchase of NUVB, presented on a split-history-adjusted basis factoring in the complete Nuvation Bio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/27/2020 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$9.75 |
|
| End price/share: |
$2.62 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-73.13% |
|
| Average Annual Total Return: |
-30.14% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,687.86 |
|
| Years: |
3.66 |
|
|
|
|
|
